Aberrant PI3K signaling in cancer can also occur via PTEN abnormalities including mutations, promotor hypermethylation or loss of heterozygosity; AKT isoform mutations or amplifications can occur as well (reviewed by Sadeghi and Gerber [55]). This evidence concerns the gene PIK3CD and cancer.